New Delhi: Zydus Cadila medicine company on Saturday said it had received approval from US health regulators to market injection of Dekitabine, used to treat certain types of cancer, in the American market.
The company has received the final approval of the US Food and Medicine Administration (USFda) to Decitabine for injection in the strength of 50 mg / single vial vial dose, Zydus Cadila said in a statement.
Decitabine is used to treat myelodysplastic syndrome, specific blood type or cancer bone cancer.
Drugs will be produced in group injection manufacturing facilities, the drug maker said.
Zydus Group now has 326 agreements and has so far submitted more than 400 new drug applications (Andas) since the start of the archiving process in 2003-04, he added.
Zydus Cadila got a nod of Usfda to market generic cancer drugs in the US
